Promethera Therapeutics is a Belgian biotechnology company specialized in the treatment of liver disease using cell therapy. It was founded in 2009 by the Technology Transfer Office of the Université Catholique de Louvain and Professor Etienne Sokal, based on the discovery made by the research and clinical team at UCL. Prof Sokal is a leading expert in hepatology and cell therapy.
Promethera® HepaStem is a cell-based therapy for the treatment of both orphan liver-based metabolic diseases and acquired liver diseases. The originality of the therapy is that a wide variety of diseases can be addressed with the same product.
Promethera Therapeutics is now launching its second clinical trial to assess the efficacy of HepaStem in Urea Cycle Disorder patients. The company is currently recruiting patients.
Promethera® HepaStem is a cell-based therapy for the treatment of both orphan liver-based metabolic diseases and acquired liver diseases. The originality of the therapy is that a wide variety of diseases can be addressed with the same product.
Promethera Therapeutics is now launching its second clinical trial to assess the efficacy of HepaStem in Urea Cycle Disorder patients. The company is currently recruiting patients.
Location: Belgium, Walloon Brabant, Mont-Saint-Guibert
Employees: 51-200
Phone: +32 10 39 43 00
Total raised: $206.63M
Founded date: 2021
Investors 7
| Date | Name | Website |
| - | Mitsui Glo... | mitsui-glo... |
| - | Korea Inve... | partners.k... |
| - | Invest.BW | investbw.b... |
| - | Fund+ | fundplus.b... |
| - | Le Groupe ... | sriw.be |
| - | Beyond Nex... | beyondnext... |
| - | Ci:z Inves... | cizinvestm... |
Funding Rounds 7
| Date | Series | Amount | Investors |
| 30.06.2021 | - | $23.75M | - |
| 16.12.2019 | Series D | $52.56M | - |
| 07.05.2019 | Series D | $44.8M | - |
| 10.04.2018 | - | $11.5M | - |
| 28.10.2016 | Series C | $10.99M | - |
| 25.11.2014 | Series C | $31.6M | - |
| 29.03.2012 | Series B | $31.43M | - |
Persons 6
| Date | First Name | Last Name | Title | Location | |||
| - | Joel | Hare | Office Man... | linkedin.c... | - | j*******e@... | - |
| - | Tuba | Baran | R&D Sc... | linkedin.c... | - | t********n... | - |
| - | Etienne | Sokal, MD,... | - | linkedin.c... | - | e*********... | - |
| - | Colin | Mudd | Quality As... | linkedin.c... | - | c********d... | - |
| - | - | - | - | twitter.co... | - | a*********... | - |
| - | Corinne | Audouin | Director I... | linkedin.c... | - | c*********... | - |
Mentions in press and media 17
| Date | Title | Description |
| 17.12.2019 | Daily funding roundup - December 17th, 2019 | GrowthPlug raised $1M; Rebank landed $2.8M; Xendoo secured $3.5M; Oto.ai closed $5.3M GrowthPlug: GrowthPlug is a healthcare software startup that aims to help healthcare practices acquire, retain, and serve patients by automating various o... |
| 17.12.2019 | Promethera Biosciences, a Belgian startup that works on treating liver diseases secures funding | Nonalcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease. It is diagnosed by conditions such as a fatty liver, liver cell damage, and inflammation. If it is not treated on time, NASH can lead to furth... |
| 16.12.2019 | Promethera Receives €7.5M Investment; Closes €47.2M Series D | Promethera Biosciences SA, a Mont-Saint-Guibert, Belgium-based global innovator in cell-based medicines and liver diseases, added €7.5m in funding to its recent €39.7m Series D financing. The round was led by new investors Sony Innovation F... |
| 06.12.2019 | Best of 2019: 10 Belgium tech startups that scored maximum funding this year | Entrepreneurs in Belgium eyeing to raise funds might have an easier time right now to grow their rice as the startup ecosystem in the country is heating up. Not only funding but also starting a business in Belgium does not take as much effo... |
| 07.05.2019 | Promethera Biosciences Completes $44.4M Series D Financing | Promethera Biosciences, a global innovator in cell-based medicines and liver diseases, closed a €39.7m (JPY4.94 billion) Series D financing. The round was co-led by new Japanese investors ITOCHU Corporation, who contributed €10m to this fin... |
| 07.05.2019 | Belgium's liver-focused stem cell therapy developer Promethera raises $44M+ in latest round | Betting on its stem cell therapy for end-stage liver disease, Belgium-based Promethera Biosciences has got €39.7 million (about $44.4 million) in the bank to develop the drug as an alternative to often hard-to-procure trans... |
| 07.05.2019 | Daily funding roundup - May 7th, 2019 | Hubtype raised $1.1M; Virtuous closed $3M; MedCrypt landed $5.3M; CollegeDekho secured $8M Aito: Aito gives new meaning to intuitive and safe operation of electronic devices. Aito has raised €1 million in seed funding, including from Nokia ... |
| 06.05.2019 | Promethera raises €40M to fund trial of NASH cell therapy | Promethera Biosciences has raised €39.7 million ($44.4 million) to put its liver disease cell therapy through clinical trials. The series D round comes as Promethera prepares to start testing its lead drug in end-stage NASH patients. Belgia... |
| 06.05.2019 | Promethera raises €40M to fund trial of NASH cell therapy | Promethera Biosciences has raised €39.7 million ($44.4 million) to put its liver disease cell therapy through clinical trials. The series D round comes as Promethera prepares to start testing its lead drug in end-stage NASH patients. Sponso... |
| 03.08.2018 | Cell Medica scoops Kite Pharma's Chris Nowers as CEO; Shire vet jumps to EdiGene as CEO | → With several of Cell Medica’s programs on track for clinical trials, Gregg Sando has decided it’s time to pass the reins at the biotech he founded 12 years ago. The new CEO is Chris Nowers, a Bristol-Myers vet and one-time b... |
Show more